KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $138.9 million.

  • Vir Biotechnology's Shares Outstanding (Weighted Average) rose 166.58% to $138.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.9 million, marking a year-over-year increase of 166.58%. This contributed to the annual value of $136.2 million for FY2024, which is 157.75% up from last year.
  • Vir Biotechnology's Shares Outstanding (Weighted Average) amounted to $138.9 million in Q3 2025, which was up 166.58% from $138.4 million recorded in Q2 2025.
  • In the past 5 years, Vir Biotechnology's Shares Outstanding (Weighted Average) registered a high of $138.9 million during Q3 2025, and its lowest value of $127.7 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $134.2 million (2023), whereas its average is $134.4 million.
  • In the last 5 years, Vir Biotechnology's Shares Outstanding (Weighted Average) soared by 1785.69% in 2021 and then soared by 114.94% in 2023.
  • Vir Biotechnology's Shares Outstanding (Weighted Average) (Quarter) stood at $129.9 million in 2021, then grew by 2.1% to $132.6 million in 2022, then increased by 1.15% to $134.1 million in 2023, then grew by 1.58% to $136.2 million in 2024, then rose by 1.97% to $138.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $138.9 million for Q3 2025, versus $138.4 million for Q2 2025 and $137.5 million for Q1 2025.